What is Behavidence?
Founded in 2020 by a multidisciplinary team of neuroscientists, physicians, and bioengineers, Behavidence specializes in the development of machine learning tools that detect and manage mental health conditions. The company's core technology utilizes passive digital biomarkers to provide real-time feedback on conditions such as depression, anxiety, and ADHD. By offering a zero-respondent-burden solution, Behavidence enables health organizations and enterprises to monitor employee burnout, predict condition relapse, and facilitate remote clinical interventions. The platform is distinguished by its commitment to user privacy and its ability to integrate seamlessly into existing health management workflows, making it a disruptive force in the digital health market.
How much funding has Behavidence raised?
Behavidence has raised a total of $4.3M across 1 funding round:
Angel/Seed
$4.3M
Angel/Seed (2022): $4.3M with participation from Arc Impact, Longevity Venture Partners, and Welltech Ventures
Key Investors in Behavidence
Arc Impact
Arc Impact is a venture firm dedicated to early-stage investments in sectors including healthcare, assistive technologies, and workforce training. They focus on supporting startups that drive positive social outcomes and improve accessibility to essential health services.
Longevity Venture Partners
Longevity Venture Partners is an early-stage venture capital firm specializing in the Silvertech, Healthcare, and Wellness sectors. They leverage a global network of experts to accelerate the growth of companies focused on longevity and health advancements.
Welltech Ventures
WellTech Ventures is a specialized fund focused on the wellness technology ecosystem, investing in startups that integrate data science and life sciences. They provide mentorship and strategic access to help companies innovate in personalized medicine and mental health.
What's next for Behavidence?
With the successful closure of this major enterprise-level funding, Behavidence is strategically positioned to accelerate its product roadmap and broaden its market penetration. The company intends to utilize this investment to enhance its predictive modeling capabilities and scale its digital phenotyping solutions for broader clinical adoption. Future growth initiatives will likely focus on deepening partnerships with government and commercial entities to standardize measurement-based care. As the industry shifts toward proactive, data-driven mental health management, Behavidence is well-equipped to lead the transition, leveraging its unique combination of engineering and clinical expertise to improve patient outcomes on a global scale.
See full Behavidence company page
